Cutting Edge Medical Research Ideas Receive £23.2 Million Boost The Medical Research Council is accelerating innovative medical research with £23.2 million in new funding to take ground-breaking ideas from UK universities into industry and out to patients. [Medical Research Council] Press Release Government of Canada Invests in Research Commercialization The Centre for Commercialization of Cancer Immunotherapy will receive funding of $15 million over five years to develop, translate and commercialize cancer immunotherapy. [Networks of Centres of Excellence of Canada] Press Release CIRM Invests in Treatment Focused on High Risk Blood Cancers, Leukemia and Lymphoma Cord blood transplants can be life saving for people battling deadly blood cancers, but they can also cause complications that are life-threatening. That’s why the California Institute for Regenerative Medicine (CIRM) has approved almost $3.5 million to fund a program to find a more effective, efficient and safer way to deliver those transplants. [California Institute for Regenerative Medicine] Press Release UTA Researcher Earns NSF CAREER Grant to Develop Conductive Bioelastomers for More Effective, Safer Tissue Engineering Yi Hong, an assistant professor of bioengineering, has won a five-year, $500,000 National Science Foundation (NSF) Early Career Development, or CAREER, Program grant to create conductive, single-component and biodegradable elastomers. [The University of Texas at Arlington] Press Release Cancer MoonShot 2020 Announces the Formation of a National Pediatrics Consortium, a Major Milestone in the War on Cancer in Children Cancer MoonShot 2020 announced another milestone in its quest to alter the course of cancer care with the formation of the Pediatrics Consortium focused on bringing the promise of combined immunotherapy as the next-generation standard of cancer care to children diagnosed with the disease. [Cancer MoonShot 2020] Press Release AVROBIO Inc. Launches to Develop Novel, Clinical-Stage Cell and Gene Therapies Targeting Immuno-Oncology and Rare Diseases AVROBIO announced its launch plans to accelerate development of two novel cell and gene therapies. Phase I programs will be in the clinic by early to mid-2016 in both acute myeloid leukemia and Fabry disease. [AVROBIO Inc.] Press Release ImmunoCellular Therapeutics Enters into Research Agreement with Stanford University to Advance Stem-to-T-Cell Program ImmunoCellular Therapeutics, Ltd. announced it has entered into an agreement with Stanford University for an option to evaluate and license intellectual property related to the identification of T cell receptors developed in the laboratory of Prof. Mark Davis at Stanford University School of Medicine. [ImmunoCellular Therapeutics, Ltd.] Press Release BioTime and Asterias Sign Share Transfer Agreement and Cross-License Agreement for Pluripotent Stem Cell Related Patents Asterias Biotherapeutics, Inc. and BioTime, Inc. and BioTime’s wholly owned subsidiary ES Cell International Pte Ltd, have entered into a Share Transfer Agreement through which BioTime will re-acquire from Asterias shares of capital stock of BioTime subsidiaries Cell Cure Neurosciences Ltd and OrthoCyte Corporation. [BioTime, Inc.] Press Release Gene Therapy for Parkinson’s Disease to Be Tested by Pitt, UPMC Experts Experts at the University of Pittsburgh School of Medicine are leading the second arm of a clinical trial using gene therapy to relieve the symptoms of tremor and mobility impairment in patients with Parkinson’s disease. [University of Pittsburgh School of Medicine] Press Release Medigene Secures Additional Viral Vector Production Capacities for Its Clinical TCR Studies Medigene AG has signed an agreement with the contract manufacturer EUFETS GmbH for the production and delivery of viral vectors. These viral vectors are required for Medigene’s upcoming clinical T-cell receptor (TCR) studies. [Medigene AG] Press Release |